The place of cyclosporin in the management of primary nephrotic syndrome

Claudio Ponticelli, Patrizia Passerini

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

The 3 main causes of primary nephrotic syndrome are minimal change nephropathy, focal segmental glomerulosclerosis and membranous nephropathy. Corticosteroids result in remission of proteinuria in most patients with minimal change nephropathy. Many patients, however, develop corticosteroid dependency. A course of cytotoxic drugs can also achieve remission but these agents cannot be administered for prolonged periods or in repeated cycles because their toxicity is cumulative. Review of the available literature indicates that cyclosporin may maintain remission of nephrotic syndrome in about 80% of patients with corticosteroid-sensitive disease, indicating an important role for this drug in patients with frequent relapses or corticosteroid dependency. Although cyclosporin is less effective in patients with focal segmental glomerulosclerosis, which is often corticosteroid- resistant, a number of studies indicate that it may be successful both in the few steroid-sensitive patients with frequent relapses and in some corticosteroid-resistant patients. In patients with membranous nephropathy, a 6-month course of corticosteroids and cytotoxic agents may favour remission of nephrotic syndrome and protect renal function. Several studies have shown that cyclosporin can improve proteinuria, and there is a tentative suggestion that it might also protect against renal function deterioration. The risk of nephrotoxicity can be minimised if cyclosporin is used at the correct doses and if renal function is carefully monitored during treatment. In summary, cyclosporin can be considered a useful tool for treating patients with nephrotic syndrome associated with primary glomerulonephritis.

Original languageEnglish
Pages (from-to)327-341
Number of pages15
JournalBioDrugs
Volume12
Issue number5
Publication statusPublished - 1999

Fingerprint

Nephrotic Syndrome
Cyclosporine
Adrenal Cortex Hormones
Lipoid Nephrosis
Focal Segmental Glomerulosclerosis
Membranous Glomerulonephritis
Kidney
Proteinuria
Recurrence
Cytotoxins
Glomerulonephritis
Pharmaceutical Preparations
Steroids

ASJC Scopus subject areas

  • Immunology and Allergy
  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Ponticelli, C., & Passerini, P. (1999). The place of cyclosporin in the management of primary nephrotic syndrome. BioDrugs, 12(5), 327-341.

The place of cyclosporin in the management of primary nephrotic syndrome. / Ponticelli, Claudio; Passerini, Patrizia.

In: BioDrugs, Vol. 12, No. 5, 1999, p. 327-341.

Research output: Contribution to journalArticle

Ponticelli, C & Passerini, P 1999, 'The place of cyclosporin in the management of primary nephrotic syndrome', BioDrugs, vol. 12, no. 5, pp. 327-341.
Ponticelli, Claudio ; Passerini, Patrizia. / The place of cyclosporin in the management of primary nephrotic syndrome. In: BioDrugs. 1999 ; Vol. 12, No. 5. pp. 327-341.
@article{52904aac11634b0eb37b39790b764d43,
title = "The place of cyclosporin in the management of primary nephrotic syndrome",
abstract = "The 3 main causes of primary nephrotic syndrome are minimal change nephropathy, focal segmental glomerulosclerosis and membranous nephropathy. Corticosteroids result in remission of proteinuria in most patients with minimal change nephropathy. Many patients, however, develop corticosteroid dependency. A course of cytotoxic drugs can also achieve remission but these agents cannot be administered for prolonged periods or in repeated cycles because their toxicity is cumulative. Review of the available literature indicates that cyclosporin may maintain remission of nephrotic syndrome in about 80{\%} of patients with corticosteroid-sensitive disease, indicating an important role for this drug in patients with frequent relapses or corticosteroid dependency. Although cyclosporin is less effective in patients with focal segmental glomerulosclerosis, which is often corticosteroid- resistant, a number of studies indicate that it may be successful both in the few steroid-sensitive patients with frequent relapses and in some corticosteroid-resistant patients. In patients with membranous nephropathy, a 6-month course of corticosteroids and cytotoxic agents may favour remission of nephrotic syndrome and protect renal function. Several studies have shown that cyclosporin can improve proteinuria, and there is a tentative suggestion that it might also protect against renal function deterioration. The risk of nephrotoxicity can be minimised if cyclosporin is used at the correct doses and if renal function is carefully monitored during treatment. In summary, cyclosporin can be considered a useful tool for treating patients with nephrotic syndrome associated with primary glomerulonephritis.",
author = "Claudio Ponticelli and Patrizia Passerini",
year = "1999",
language = "English",
volume = "12",
pages = "327--341",
journal = "Clinical Immunotherapeutics",
issn = "1173-8804",
publisher = "Adis International Ltd",
number = "5",

}

TY - JOUR

T1 - The place of cyclosporin in the management of primary nephrotic syndrome

AU - Ponticelli, Claudio

AU - Passerini, Patrizia

PY - 1999

Y1 - 1999

N2 - The 3 main causes of primary nephrotic syndrome are minimal change nephropathy, focal segmental glomerulosclerosis and membranous nephropathy. Corticosteroids result in remission of proteinuria in most patients with minimal change nephropathy. Many patients, however, develop corticosteroid dependency. A course of cytotoxic drugs can also achieve remission but these agents cannot be administered for prolonged periods or in repeated cycles because their toxicity is cumulative. Review of the available literature indicates that cyclosporin may maintain remission of nephrotic syndrome in about 80% of patients with corticosteroid-sensitive disease, indicating an important role for this drug in patients with frequent relapses or corticosteroid dependency. Although cyclosporin is less effective in patients with focal segmental glomerulosclerosis, which is often corticosteroid- resistant, a number of studies indicate that it may be successful both in the few steroid-sensitive patients with frequent relapses and in some corticosteroid-resistant patients. In patients with membranous nephropathy, a 6-month course of corticosteroids and cytotoxic agents may favour remission of nephrotic syndrome and protect renal function. Several studies have shown that cyclosporin can improve proteinuria, and there is a tentative suggestion that it might also protect against renal function deterioration. The risk of nephrotoxicity can be minimised if cyclosporin is used at the correct doses and if renal function is carefully monitored during treatment. In summary, cyclosporin can be considered a useful tool for treating patients with nephrotic syndrome associated with primary glomerulonephritis.

AB - The 3 main causes of primary nephrotic syndrome are minimal change nephropathy, focal segmental glomerulosclerosis and membranous nephropathy. Corticosteroids result in remission of proteinuria in most patients with minimal change nephropathy. Many patients, however, develop corticosteroid dependency. A course of cytotoxic drugs can also achieve remission but these agents cannot be administered for prolonged periods or in repeated cycles because their toxicity is cumulative. Review of the available literature indicates that cyclosporin may maintain remission of nephrotic syndrome in about 80% of patients with corticosteroid-sensitive disease, indicating an important role for this drug in patients with frequent relapses or corticosteroid dependency. Although cyclosporin is less effective in patients with focal segmental glomerulosclerosis, which is often corticosteroid- resistant, a number of studies indicate that it may be successful both in the few steroid-sensitive patients with frequent relapses and in some corticosteroid-resistant patients. In patients with membranous nephropathy, a 6-month course of corticosteroids and cytotoxic agents may favour remission of nephrotic syndrome and protect renal function. Several studies have shown that cyclosporin can improve proteinuria, and there is a tentative suggestion that it might also protect against renal function deterioration. The risk of nephrotoxicity can be minimised if cyclosporin is used at the correct doses and if renal function is carefully monitored during treatment. In summary, cyclosporin can be considered a useful tool for treating patients with nephrotic syndrome associated with primary glomerulonephritis.

UR - http://www.scopus.com/inward/record.url?scp=0032747225&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032747225&partnerID=8YFLogxK

M3 - Article

VL - 12

SP - 327

EP - 341

JO - Clinical Immunotherapeutics

JF - Clinical Immunotherapeutics

SN - 1173-8804

IS - 5

ER -